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Cytochrome P450 monooxygenases (P450s) are attractive enzymes for the
pharmaceutical industry, in particular, for applications in steroidal drug syn-
thesis. Here, we report a comprehensive functional and structural characteri-
zation of CYP109E1, a novel steroid-converting cytochrome P450 enzyme
identified from the genome of Bacillus megaterium DSM319. In vitro and
whole-cell in vivo turnover experiments, combined with binding assays,
revealed that CYP109E1 is able to hydroxylate testosterone at position 16b.
Related steroids with bulky substituents at carbon C17, like corticosterone,
bind to the enzyme without being converted. High-resolution X-ray struc-
tures were solved of a steroid-free form of CYP109E1 and of complexes with
testosterone and corticosterone. The structural analysis revealed a highly
dynamic active site at the distal side of the heme, which is wide open in the
absence of steroids, can bind four ordered corticosterone molecules simulta-
neously, and undergoes substantial narrowing upon binding of single steroid
molecules. In the crystal structures, the single bound steroids adopt unpro-
ductive binding modes coordinating the heme-iron with their C3-keto oxy-
gen. Molecular dynamics (MD) simulations suggest that the steroids may
also bind in ~180° reversed orientations with the C16 carbon and C17-substi-
tuents pointing toward the heme, leading to productive binding of testos-
terone explaining the observed regio- and stereoselectivity. The X-ray
structures and MD simulations further identify several residues with impor-
tant roles in steroid binding and conversion, which could be confirmed by
site-directed mutagenesis. Taken together, our results provide unique insights
into the CYP109E1 activity, substrate specificity, and regio/stereoselectivity.
Database
The atomic coordinates and structure factors have been deposited in the Protein Data Bank
with accession codes 5L90 (steroid-free CYP109E1), 5L91 (CYP109E1-COR4), 5L94
(CYP109E1-TES), and 5L92 (CYP109E1-COR).
Enzymes
Cytochrome P450 monooxygenase CYP109E1, EC 1.14.14.1, UniProt ID: D5DKI8, Adreno-
doxin reductase EC 1.18.1.6.
Abbreviations
COR, corticosterone; P450, cytochrome P450 monooxygenase; SRS, substrate recognition site; TES, testosterone.
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Introduction
Cytochrome P450 monooxygenases (P450s) constitute
a large superfamily of enzymes, found in all domains
of life, which catalyze oxygen-mediated hydroxylation
of a wide variety of aromatic and aliphatic com-
pounds. In nature, these enzymes play essential roles
in metabolic processes like steroid biosynthesis, fatty
acid metabolism, or biotransformation of drugs and
other xenobiotics. In the laboratory and biotechno-
logical industry, they are considered as high potential
biocatalysts, owing to their ability to selectively oxi-
dize unreactive C-H bonds at mild conditions [1].
Their application toward cost-effective and environ-
mentally friendly production of steroid derivatives is
of particular interest, considering the wide use of such
compounds as therapeutic agents [2,3]. Currently
more than 300 steroid drugs are authorized, making
them the most marketed group of products in the
pharmaceutical industry [4]. The ability of P450s to
perform regioselective and stereoselective hydroxyla-
tion of steroids has led to an ongoing search and
characterization of new enzymes, in particular from
prokaryotic sources, as these are more amenable to
industrial application than their eukaryotic counter-
parts [5].
To efficiently handle P450s and to design improved
variants for synthetic applications, it is crucial to
understand the structure-function relationships govern-
ing their substrate specificity and regio- and stereose-
lectivity [6,7]. Although a wealth of functional and
structural data are available for these enzymes, it has
proven difficult to pinpoint the molecular determi-
nants of their different specificities. Crystal structures
of P450 enzymes from mammalian and bacterial
sources have revealed a high conformational variabil-
ity, despite their common overall fold [8–10]. In par-
ticular, a few characteristic, highly flexible regions
around the P450 distal heme pocket (the BC loop, F
and G helices together with the FG loop) are associ-
ated with substrate access, substrate binding and pro-
duct release. Understanding substrate binding and
conversion by P450s requires the analysis of crystallo-
graphic ‘snapshots’ of their open (substrate-free) and
closed (substrate-bound) states, which frequently are
not available for individual P450s. Combining findings
from X-ray crystallography, computational docking,
and MD simulations has significantly increased the
understanding of mammalian and bacterial P450s
[11,12]. Nevertheless, for new, soluble, prokary-
otic P450s, structural characterization is indispensable
for adapting them to specific biotechnological
applications.
To date, only a few bacterial steroid-specific P450s
have been functionally and structurally characterized.
Recently published examples include CYP106A2 from
Bacillus megaterium ATCC 13368 [13], CYP154C5
from Nocardia farcinica [14], CYP154C3 from Strepto-
myces griseus [15], and CYP109B1 from Bacillus
subtilis [16]. Of these, CYP154C5 is of particular inter-
est, as it exhibits an exceptionally high regio- and
stereoselectivity to various pregnanes and androstanes,
including pregnenolone, progesterone, testosterone,
and androstenedione, yielding only 16a-hydroxylated
steroids. Crystal structures of steroid-bound
CYP154C5 reveal a narrow, nearly closed active site,
mostly hydrophobic with two opposing polar regions,
perfectly matching the size and polarity distribution of
the steroids. The apolar/polar shape complementarity
leads to a highly ordered binding mode of the steroids,
with the a-face of their C16 carbon at a suitable
distance from the heme-iron for allowing a radical
attack by the reactive iron-oxo species (compound I)
of the catalytic cycle, thus explaining the high regio-
and stereoselectivity of the enzyme. Of the other two
enzymes, CYP109B1 is of interest as it represents the
first member of the CYP109 family of which a crys-
tal structure has been determined. It was crystallized
in an ‘open’ conformation with no ligands bound in
the active site. Sequence alignment with different
CYP109 family members, and members of related
P450 families, suggested that variations in the so
called BC loop, one of the common P450 regions
involved in substrate binding, may primarily account
for the diverse substrate specificities among these
enzymes.
Recently, the genomes of Bacillus megaterium
DSM319 [17] and ATCC 13368 were sequenced, allow-
ing exploration of their cytochrome P450 complement.
Its analysis has resulted in the identification and char-
acterization of several novel steroid-converting P450s
[18–21]. Here, we report the functional and structural
properties of CYP109E1 from B. megaterium
DSM319. Using in vitro and in vivo turnover experi-
ments, we demonstrate that the enzyme converts
testosterone to 16b-hydroxytestosterone with a high
stereo- and regioselectivity. Crystal structures of
CYP109E1 were determined both in steroid-free and
steroid-bound states allowing a detailed analysis of the
interactions and conformational changes associated
with steroid binding. In addition, we employed MD
simulations to test putative productive steroid-binding
modes in the active site pocket of CYP109E1, leading
to a better understanding of the structural determi-
nants of the enzyme’s activity.
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Results
Identification and bioinformatic analysis of
CYP109E1
The cyp109e1 gene was identified in the genome of
B. megaterium DSM319 by the same bioinformatic
search strategy used previously for identifying
cyp106a1 [20]. A multiple amino acid sequence align-
ment of CYP109E1 (UniProtKB entry d5dki8) with its
closest homologs is presented in Fig. 1. Classification
of the enzyme into the CYP109 family was based on
the conventional P450 nomenclature system [22].
Indeed, CYP109E1 shares close similarity with other
characterized CYP109 family members, that is,
CYP109B1 from B. subtilis strain 168 (47% sequence
identity), CYP109A1 from B. subtilis strain W23 (43%
sequence identity), and the three fatty acid-oxidizing
proteins CYP109C1, CYP109C2, and CYP109D1 from
Sorangium cellulosum strain So ce56 (39%, 41%, and
33% sequence identity, respectively) [16,23,24]. How-
ever, the phylogenetic tree (Fig. 2) indicates that
CYP109E1 shares the closest similarity with
CYP106A1 from the same organism (42% amino acid
sequence identity). This close relationship, which has
been noted also for other CYP109 and CYP106 family
members from Bacillus species [25], may indicate that
these enzymes convert similar substrates.
Expression, purification, and spectroscopic
characterization of CYP109E1
CYP109E1 was expressed in E. coli as a soluble pro-
tein, containing the gene-encoded residues 1–404,
fused to a C-terminal polyhistidine tag. Purification
was accomplished by employing a three-step purifica-
tion strategy, including anion-exchange, size-exclu-
sion, and mixed mode ion-exchange chromatography.
Immobilized metal ion affinity chromatography was
on purpose excluded from the purification protocol
to eliminate the risk of imidazole affecting the func-
tional assays and crystallization experiments. Typi-
cally, 25 mg of pure protein was obtained from
0.5 L of expression culture, with an estimated purity
of > 95% as judged by SDS/PAGE. Analysis of
UV-visible absorption and reduced CO-difference
spectra of reduced CYP109E1 revealed all character-
istic P450 peaks, confirming the structural integrity
of the protein with correct incorporation of the
heme cofactor. The purified protein thus obtained
was used for subsequent functional and structural
characterization.
Substrate screening, conversion, and product
identification
Considering the close phylogenetic distance between
CYP109E1 and CYP106A1, it was proposed that ster-
oids being substrates of CYP106A1 could also be suit-
able ligands for CYP109E1. The potential of
CYP109E1 as a steroid hydroxylase was, therefore,
tested in ligand-binding experiments using a library of
13 steroids (Table 1, see Table S2 for chemical struc-
tures). Six steroids induced a type I spectral shift upon
titration to CYP109E1: androstenedione (1), corticos-
terone (4), deoxycorticosterone (5), dexamethasone (7),
testosterone (11), and testosterone acetate (12), indicat-
ing displacement of the axial heme water and thus
marking them as potential CYP109E1 substrates.
However, several studies have shown that, on one
hand, not all compounds inducing type I shift are
substrates of P450s [19,26,27] while, on the other
hand, substrates do not always induce a type I spectral
shift [18]. Consequently, all 13 steroids were further
subjected to an in vitro CYP109E1-dependent enzy-
matic conversion assay, using bovine adrenodoxin and
adrenodoxin reductase (Adx4–108 and AdR) as surro-
gate redox partners for the reconstitution of P450
activity. Most steroids were not converted by
CYP109E1 (including all steroids which did not induce
a type I spectral shift) or showed only very low to neg-
ligible conversion rates (< 10%). Only testosterone
(11) showed substantial turnover by CYP109E1, and
analysis of the reaction mixture by HPLC revealed one
main (69%) and one minor (14%) product (Fig. 3), with
a catalytic activity of 4.35 and 0.93 nmol pro-
duct(nmol P450)1min1, respectively. Structure
determination of these products by NMR spectroscopy
required a substantial increase in their amounts, which
could not easily be accomplished with the in vitro
activity assay. This was the incentive for developing a
B. megaterium whole-cell system overexpressing
Fig. 1. Multiple sequence alignment of CYP109E1 with P450s identified in B. megaterium DSM319 and other known CYP109 family
members. Secondary structural elements are shown as in the substrate-free CYP109E1 crystal structure (helices labeled A–L). Conserved
and similar residues are highlighted in red and yellow, respectively. Highly conserved, functionally relevant regions (central part of I helix,
EXXR motif and heme-binding domain signature) are shown with violet frames. For all sequences shown, the UniProtKB accession numbers
are the same as used in the phylogenetic tree (Figure 2) (for CYP102A1 only residues 1–472 of the heme domain are shown).
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CYP109E1, thus allowing the conversion of substrates
under more optimal in vivo conditions and without the
need of surrogate P450 redox partners. Testosterone
turnover by CYP109E1 was successfully reproduced in
the B. megaterium whole-cell system, enabling conver-
sion of 26 mg of testosterone (300 lM) within 6 h to
19 mg and 5 mg of the main and minor product,
respectively. Structure elucidation by NMR identified
the main product as 16b-hydroxytestosterone and the
side product as androstenedione (Table S3). The for-
mation of androstenedione as a side product may be
the result of a weak hydroxylation activity toward the
C17 atom of testosterone, yielding a 17,17-gem-diol
intermediate that subsequently dehydrates to the corre-
sponding oxocarbon.
To investigate whether the differences in the conver-
sion of compounds inducing a type I spectral shift are
due to major differences in binding to CYP109E1, we
compared the affinities of testosterone (converted sub-
strate) and corticosterone (bound, but not converted).
Quantitative analysis of the spectral shift titration data
revealed that both compounds displayed very similar
binding affinities to CYP109E1 with a dissociation
constant (KD) of 105  10 lM and 91  8 lM, respec-
tively (Fig. 4). Thus, the highly selective activity of
CYP109E1 toward testosterone, versus no conversion
of corticosterone, is not correlated with a difference in
steroid-binding affinity. In summary, the functional
experiments revealed that CYP109E1 displays a rather
narrow steroid-binding specificity, with relatively
weak-binding affinities, and is able to hydroxylate
testosterone to 16b-hydroxytestosterone with very high
regio- and stereoselectivity.
Overall structure of steroid-free CYP109E1
To evaluate the structural basis for the selectivity of
steroid binding and conversion, crystallization of
CYP109E1 in the presence and absence of a sub-
strate was performed. Purified CYP109E1 was suc-
cessfully crystallized in the absence of steroids, and
its crystal structure was solved and refined to a 2.55
A resolution (see Table 2 for the relevant data col-
lection and refinement statistics). The CYP109E1
crystals contain two protein molecules in the asym-
metric unit. Both polypeptide chains, and their asso-
ciated heme cofactors, are well defined in the
electron density, except for residues 1–20 and the C-
terminal His6-tags. Since the two crystallographically
independent CYP109E1 molecules have nearly identi-
cal conformations [the root mean square deviation
(RMSD) of Ca-backbone atoms is 0.34 A for 374
aligned residues], we will restrict the description to
only one of them. CYP109E1 adopts the characteris-
tic triangular ‘P450-fold’ and contains 13 a-helices,
two 310 helices, and 10 b-strands (arranged in a five-
stranded sheet, three-stranded sheet, and a b-finger,
Fig. 5A). The overall fold of the P450 enzyme is well
conserved: the closest structural homolog of
CYP109E1 is substrate-free CYP109B1 from B. sub-
tilis (PDB entry 4rm4, RMSD of Ca-backbone atoms
of 1.19 A for 347 common residues). A unique fea-
ture of the CYP109E1 structure is presented by its
G helix (following nomenclature of secondary
Fig. 2. Phylogenetic tree of the CYP109 family members and
related P450s from B. megaterium DSM319. P450s from
B. megaterium DSM319 are indicated with a closed circle (•).
CYP109C1, CYP109C2, and CYP109D1 are from
Sorangium cellulosum So ce56; CYP109A1 and CYP109B1 are from
B. subtilis W23 and 168, respectively. The UniProtKB accession
numbers are given next to the associated CYP names. The tree is
drawn to scale, with branch lengths in the same units as those of
the evolutionary distances used to infer the phylogenetic tree.
Table 1. Steroid binding and in vitro conversion activity of
CYP109E1 toward selected steroids. Chemical structures of the
steroids are shown in supplementary Table S2. The + and 
indicate positive and negative outcomes of what is stated in the
column headers.
Compound Type I shift In vitro conversion
Androstenedione (1) + + (< 10%)
Cortisol (2)  
Cortisone (3)  
Corticosterone (4) +  (< 2%)
Deoxycorticosterone (5) + + (< 7%)
11-deoxycortisol (6)  
Dexamethasone (7) + 
Prednisolone (8)  
Prednisone (9)  
Progesterone (10)  
Testosterone (11) + +
Testosterone acetate (12) + + (< 10%)
19-nortestosterone (13)  
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structural elements established by Poulos et al. [28]),
which is significantly longer than in other bacterial
P450 structures. A structural comparison with other
P450s further reveals that steroid-free CYP109E1
adopts an open conformation with a spacious active
site pocket at the distal side of the heme, which is
freely accessible to solvent (Fig. 5B). The heme
cofactor is bound between the I and L helices, with
the thiolate group of Cys352 serving as the fifth
ligand of the heme-iron. No electron density was
observed for a water molecule coordinating the
heme-iron as a sixth ligand. Instead, a small blob of
electron density was visible at about 4 A distance
from the heme, but the density was of insufficient
quality to allow identification of the bound ligand.
The noncovalent interactions between CYP109E1 and
its heme are highly similar as in other class I P450s.
Stabilization is provided by van der Waals interac-
tions between the heme core and several apolar pro-
tein side chains, and by ion pairs formed between
Fig. 3. In vitro conversion of testosterone
by purified CYP109E1. (A) Schematic
representation of the reaction and (B) HPLC
chromatogram.
Fig. 4. Type I spectral shifts induced by steroid binding to CYP109E1 and the derived binding curves. (A) Binding curve of testosterone.
(B) Binding curve of corticosterone. The spectral shifts upon titration of the steroids are shown as insets. The enzyme solution (10 lM,
50 mM potassium phosphate buffer, pH 7.4) was titrated with increasing amounts of substrates dissolved in DMSO. The peak-to-through
absorbance differences were plotted against the increasing concentrations of the substrate. Plotted data points are the mean values from
three independent measurements. Error bars represent the standard deviations. The curves were fitted by hyperbolic regression.
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the heme propionates and the side chains of highly
conserved residues His92, Arg96, Arg294, and
His350.
Active site pocket of steroid-free CYP109E1
The geometry of the active site pocket in the open
form of CYP109E1 was analyzed in more detail. As
shown in Fig. 5B, it resembles a funnel, wide open at
the entrance but becoming more constricted as it leads
toward the heme. The structural regions surrounding
the active site pocket are equivalent to the six sub-
strate recognition sites commonly found in P450s [29]:
the BC loop (substrate recognition site 1 or SRS1),
parts of the F and G helices (SRS2 and SRS3, respec-
tively), the central segment of the I helix (SRS4), the
Table 2. Data collection, refinement, and model statistics of CYP109E1.
Substrate-free CYP109E1 CYP109E1-COR4 CYP109E1-TES CYP109E1-COR
Conformation Open Open Closed & open Closed & open
PDB code 5L90 5L91 5L94 5L92
Model statistics
Monomers in the AU 2 2 2 2
Solvent content (%) 61.7 60.2 49.1 49.1










ID29 ID23-2 In-house ID23-1
Wavelength (A) 1.04541 0.87261 1.5418 0.97241
Resolution range (A) 60–2.55 (2.65–2.55)a 49–2.20 (2.26–2.20) 56–2.25 (2.32–2.25) 48–2.10 (2.16–2.10)
Space group P 32 2 1 P 32 2 1 P 1 21 1 P 1 21 1
Unit-cell parameters
a, b, c (A) 121.3, 121.3, 144.2 120.4, 120.4, 140.8 60.4, 134.9, 61.9 60.5, 135.7, 61.6
a, b, c, ° 90, 90, 120 90, 90, 120 90, 113.8, 90 90, 114.4, 90
Observed reflections 293 843 (30 950) 355 244 (26 012) 293 196 (26 695) 156 293 (12 345)
Unique reflections 40 454 (4508) 60 153 (4384) 42 810 (3945) 51 292 (12 345)
Multiplicity 7.3 (6.9) 5.9 (5.9) 6.8 (6.8) 3.0 (2.9)
Completeness (%) 99.9 (99.9) 99.7 (100) 99.7 (99.1) 97.4 (98.8)
<I/r(I)> 11.6 (2.6) 15.9 (2.3) 12.2 (2.7) 23.3 (4.1)
Rmerge (%) 9.6 (80.2) 8.7 (66.9) 14.2 (73.9) 2.8 (22.2)
CC (1/2) (%) 99.8 (84.8) 99.8 (80.1) 99.6 (83.7) 99.9 (91.4)
Refinement
Rwork (%) 21.44 18.48 21.90 20.09
Rfree (%) 25.88 23.21 26.28 24.31
R.m.s.deviation, bond lengths (A) 0.017 0.014 0.014 0.014
R.m.s.deviation, bond angles (°) 1.679 1.322 1.252 1.299
Average B-factors (A)2
Overall 73.65 46.81 40.16 42.65
Protein 73.96 46.49 40.45 42.92
Heme 48.29 28.30 27.39 28.22
Testosterone (TES) n/a n/a 35.29 n/a
Corticosterone (COR) n/a n/a n/a 43.43
COR-1 n/a 48.66 n/a n/a
COR-2 n/a 77.89 n/a n/a
COR-3 n/a 86.81 n/a n/a
COR-4 n/a 56.60 n/a n/a
Malonic acid (MLA) n/a n/a n/a 42.14
Ramachandran plot statistics
Most favored (%) 94.9 95.6 96.1 96.6
Allowed regions (%) 4.8 4.3 3.9 3.4
Disallowed regions (%) 0.3 0.1 0.00 0.00
Molprobity overall score 1.62 1.54 1.22 1.14
a Values in parentheses refer to data in the highest resolution shells.
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region connecting helix K and strand b5 (SRS5) and
the b9–b10 turn (SRS6). Close to the heme, the active
site is very hydrophobic and its surface is roughly built
of two rings of residues. The first ring (closest to the
heme) contains residues Ile85 (BC loop); Leu238,
Ala242, and Thr246 (I helix); Pro288, Val289, and
Leu292 (K-b5 loop). Many of these residues are highly
to moderately conserved among P450s, for example,
Thr246, Ala242, or Val289, in agreement with com-
mon roles in catalysis and substrate binding [30]. The
second ring contains residues Arg69, Leu80, and
Asn86 (BC loop); Ile168 and Val169 (F helix); Ile241
and Glu245 (I helix); Phe391 and Val392 (b9–b10
turn). Residues Arg69, Asn86, and Glu245 form two
polar-charged surface patches located at opposite sides
of the active site pocket. Further away from the heme,
near the entrance of the active site pocket, residues are
mostly polar charged. Active site residues in the sec-
ond ring, and residues at the entrance of the active site
pocket in CYP109E1, show substantial divergence with
respect to other P450s, including the testosterone-
hydroxylating enzymes like CYP109B1 from B. subtilis
or CYP154C5 from N. farcinica.
Structures of CYP109E1 with single bound
corticosterone or testosterone
To characterize how steroids interact with CYP109E1,
crystal structures of CYP109E1 with bound corticos-
terone (type I shift, but no substrate) or testosterone
(type I shift, substrate) (CYP109E1-COR and
CYP109E1-TES) were obtained by cocrystallization
and refined at 2.25–2.1 A resolution (see Table 2 for
details). Like the steroid-free crystals, the steroid-
bound cocrystals contain two polypeptide chains per
asymmetric unit (solvent content of 49%), yet they
belong to a different space group and show a different
crystal packing geometry. Only one of the two unique
CYP109E1 protein molecules in each cocrystal has a
bound steroid. The protein molecules lacking a bound
steroid adopt an open conformation similar to that of
steroid-free CYP109E1. No electron density is present
for the BC loop, FG loop, and several residues at the
end of the G helix, indicating that these regions are
significantly disordered. In the protein molecules with
a bound steroid, a remarkable narrowing and partial
closure of the active site pocket is observed, allowing
most substrate-binding regions to closely approach
and interact with the steroids. The F and G helices,
together with the FG loop, show the largest displace-
ment, while the BC loop and b9–b10 turn show
smaller readjustments (Fig. 6A). The central part of
the BC loop (residues 71–75) is highly disordered and
could not be resolved in the electron density map. The
conformational change in the FG helices is accompa-
nied by reorientations of the H helix and HI loop. In
addition, a local widening of the I helix is observed at
residues 242–246, creating a groove which allows close
packing of the steroids near the heme. A similar
groove in the I helix has also been observed in other
Fig. 5. Overall structure and the active site of CYP109E1. (A) Overall structure shown in ribbon representation, with rainbow coloring from
blue N’ terminus to red C’ terminus. The heme cofactor is shown in red and beta strands in gray. Secondary structural elements are labeled
following the common P450 nomenclature. (B) Active site pocket of substrate-free CYP109E1. Coloring apolar–polar, orange-blue.
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substrate-bound bacterial P450 structures, and its sub-
strate-induced conformation is believed to play an
important role in oxygen activation and proton deliv-
ery [31]. Interestingly, four ordered water molecules
are found at the interface of the I and E helix, two of
which are located in the groove of the I helix (Fig. 7).
The four waters form a continuous hydrogen-bonded
network, which includes the main-chain carbonyls of
Ala242 and Gly243, the side-chain hydroxyl groups of
Thr246 and Thr247, and the main-chain amide of
Thr248. Although the network is not directly con-
nected to bulk solvent (the distance with the nearest
water bound at the protein surface is 5.3 A), it corre-
lates well with the so called ‘solvent channel’ found in
many P450s, located between the F, E, and I helices,
which is believed to serve as a water access channel
and/or proton delivery network [32].
Electron density of the bound steroids was of suffi-
cient quality to allow a clear characterization of their
binding modes (Fig. 6B, C). Both steroids show an
unproductive binding mode: the corticosterone and
testosterone molecules are bound in roughly perpendic-
ular orientations relative to the heme plane, with their
C3-keto oxygen atoms coordinating the heme-iron at
the sixth axial position. The b-faces of the steroids are
oriented toward the I helix, while the C17 substituents
are pointing away from the heme toward the entrance
of the active site pocket. The two steroids are mainly
bound by van der Waals and hydrophobic interactions.
Residues in the active site pocket making hydrophobic
interactions with the steroids are Leu80 (BC loop,
SRS1), Ile168, Val169 (F helix, SRS2), Leu238, Ile241,
Ala242, Thr246 (I helix, SRS4), Val289, Ala291,
His293 (K/b5 connecting region, SRS5), and Phe391,
Val392 (b9–b10 turn, SRS6). No direct hydrogen
bonds are observed between the protein and the two
steroid molecules. In the structure with bound corticos-
terone, a malonic acid molecule is present in the active
site forming van der Waals contacts with ring B of the
steroid (Fig. 6C). The malonic acid molecule is further
stabilized by hydrogen bonds with His293 (SRS5) and
one of the heme-propionate groups, and by van der
Waals contacts with residues Arg69, Ile85 (SRS1),
Leu292 (SRS5), and Phe391 (SRS6). Its presence is
most likely a crystallographic artifact, as malonic acid
is the major component of tacsimate, the reagent used
in the crystallization of CYP109E1-COR.
Multiple corticosterone-bound CYP109E1
structure
An additional structure of corticosterone-bound
CYP109E1 was obtained at 2.2 A resolution by soaking
the steroid into pregrown, steroid-free crystals
(CYP109E1-COR4, Table 2). Interestingly, the corticos-
terone-soaked crystals display a water as the sixth axial
ligand of the heme-iron and multiple steroid binding
(four corticosterones, Fig. 8). For clarity, we abbreviate
the ligands as COR-1, COR-2, COR-3, and COR-4.
COR-1 is located closest to the heme-iron, while COR-4
is most distant. The protein molecules in CYP109E1-
COR4 adopt an open state, with only a minor reposition-
ing of the G helix toward the bound steroids. The limited
conformational changes compared to steroid-free
CYP109E1 are not surprising, since crystal packing inter-
actions between the neighboring protein molecules lock
the F and G helices, FG loop, and BC loop in an ‘open’
position (Fig. 8A). It is remarkable, however, that the
open state allows ordered binding of multiple steroids.
The four steroids are bound in different orientations
and show substantial intermolecular van der Waals
contacts between their steroid rings. COR-1 is pointing
with its bulky C17-substituent toward the heme and its
C21-hydroxyl group forms a hydrogen bond with a
water molecule coordinating the heme-iron (Fig. 8B).
Additional interactions of this steroid at the active site
pocket include two direct hydrogen bonds, between
the C3-keto oxygen and the side chain of Lys187
(SRS3) and between the C11-hydroxyl group and the
main-chain carbonyl oxygen of Ile241 (SRS4), two
water-mediated hydrogen bonds, between the C11-
hydroxyl group and the side chain of Glu245 and
between the C21-hydroxyl group and the main-chain
carbonyl group of Ala242 (SRS4), as well as several
hydrophobic contacts with residues Ile85 (SRS1),
Ile168, Val169 (SRS2), Thr246 (SRS4), Val289 (SRS5),
and Val392 (SRS6). The other three corticosterones
also make specific contacts with the protein (interac-
tions described in detail in Table S4).
Modeling of regio- and stereoselectivity of
CYP109E1
In the CYP109E1-TES crystal structure, the shape of
the electron density for the bound steroid suggested
that testosterone may perhaps adopt an alternative,
reversed binding mode, in which the C16 and C17 car-
bons are located close to the Fe atom (~4 A), consis-
tent with the observed activity of CYP109E1. Addition
of such a putative productive binding mode in the
refined CYP109E1-TES structure resulted in a poor fit
to the observed electron density, thus, we assume that
testosterone predominantly adopts the unproductive
binding mode in the protein crystals. Therefore, to
explore the molecular basis of its selective steroid con-
version and regio/stereoselectivity, MD simulations of
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the CYP109E1-oxoferryl species (compound I) in
complex with corticosterone or testosterone were per-
formed. Starting models for the MD simulations were
based on the CYP109E1-TES structure in which the
crystallographically observed testosterone molecule
was replaced by docked steroids (corticosterone or
testosterone) in reversed orientations, with the C16
carbon atom or C17 substituents oriented toward the
heme-iron. Steroid conversion and regio/stereoselectiv-
ity of the CYP109E/steroid complexes were modeled
by assigning each frame of the MD simulation as
being in either a near-attack conformation or in a non-
productive conformation, on the basis of distance
and angle cutoffs, following previously published
procedures [33–35]. The number of near-attack confor-
mations was the highest for MD simulations
with testosterone, where 16% of the simulation frames
revealed near-attack conformations suggesting
formation of 16b-hydroxytestosterone (pro-16b, 99%)
or androstenedione (pro-17a, 1%). No pro-16a near-
Fig. 6. Conformational changes and steroid-binding modes in CYP109E1. (A) Superposition of substrate-free CYP109E1 (gray), CYP109E1-
TES (light blue), and CYP109E1-COR (orange) showing the open–closed conformational changes. COR is shown as cyan stick model. (B)
Amino acid residues involved in testosterone binding (CYP109E1-TES) are shown and TES is shown as violet stick model. Black mesh is the
composite omit 2Fo  Fc electron density map, calculated at 2.25 A resolution and contoured at 1r. (C) Residues binding single
corticosterone and malonic acid in the active site of CYP109E1-COR (green) in comparison to substrate-free structure (gray), with COR
shown in cyan and MLA in light pink. Black mesh is the composite omit 2Fo  Fc electron density map, calculated at 2.1 A resolution and
contoured at 1r. (D) Comparison of testosterone binding modes observed in CYP109E1 (violet stick model) and CYP154C5 from N. farcinica
(in gray, PDB entry 4j6d). Amino acid residues providing stabilizing interactions in CYP154C5 are shown and compared to their structural
homologues in CYP109E1. Distances are given inangstroms next to the black dashed lines.
4137The FEBS Journal 283 (2016) 4128–4148 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
I. K. Jozwik et al. Structure of testosterone-converting CYP109E1
attack conformations occurred in the simulations, in
accordance with the observed stereoselectivity of the
enzyme. Interactions of one of the most frequently vis-
ited testosterone-binding poses were analyzed in detail
(Fig. 9). The testosterone molecule is positioned opti-
mally for abstraction of the C16b-hydrogen, and forms
hydrophobic interactions with the same residues as in
the CYP109E1-TES crystal structure, that is, Leu80
(SRS1), Ile168 (SRS2), Ile241 and Thr246 (SRS4),
Val289 (SRS5), Phe391 and Val392 (SRS6). In
addition, the testosterone C3-keto oxygen is in hydro-
gen-bonding distance to Lys187 (SRS3). In the case of
corticosterone, only 0.8% of the MD simulation
frames showed near-attack conformations (suggesting
generation of a 16a-hydroxylated product). The results
are in concordance with the lack of experimentally
observed corticosterone conversion by CYP109E1.
Site-directed mutagenesis
To substantiate the crystallographic and modeling
results, single alanine mutations were prepared of a
few selected residues (Val169, Lys187, Ile241,
Glu245, and Thr246) in the active site pocket of
CYP109E1 and their effect on CYP109E1-catalyzed
conversion of testosterone was analyzed using the
in vitro activity assay (Table 3). Replacement of
Val169 and Ile241 by alanine resulted in almost
complete abolishment of 16b-hydroxytestosterone
production, confirming the importance of these resi-
dues for productive steroid binding. The K187A
mutation also caused a decrease in activity compared
to the wild-type enzyme, but the effect is much smal-
ler than for the V169 and I241 mutations. Thus, the
hydrogen bond of the testosterone C3-keto group
with the side chain of Lys187, as observed in the
MD simulations, is not a crucial interaction for pro-
ductive binding of testosterone. Interestingly, alanine
mutations of Glu245 and Thr246 (the conserved
‘acid-alcohol’ pair) led to opposite effects on
CYP109E1 activity toward testosterone. While the
T246A mutation resulted in a drastic decrease in
16b-hydroxytestosterone production, the E245A
mutation did not significantly affect the CYP109E1
activity. These results support the relevance of the
water channel observed in the single steroid-bound
CYP109E1 structures, and implicates a role for
Thr246, but not Glu245, in proton delivery and oxy-
gen activation within the active site.
Discussion
Only a few bacterial P450s have been characterized
that are able to hydroxylate testosterone at different
positions in the steroid skeleton, with high regio- and
stereoselectivity [36]. Recent examples include
CYP109B1 from B. subtilis and CYP154C5 from
N. farcinica, which produce 15b- and 16a-hydroxy-
lated testosterone, respectively [37,38]. CYP109E1
from B. megaterium is the first example of a wild-type
bacterial P450 showing highly selective 16b-hydroxy-
lase activity toward testosterone. Production of
16b-hydroxytestosterone has previously been observed
with specific P450 BM3 mutants, obtained by protein
engineering, but these mutants do not display the same
high level of regio- and stereoselectivity as CYP109E1
[39–41]. Similarly, various mammalian P450s are able
to hydroxylate testosterone at position 16b, but they
Fig. 7. Putative proton relay network in CYP109E1. Local distortion
in the central part of I helix, upon binding of single testosterone or
corticosterone (CYP109E1-TES is depicted here) allowed for
binding of four ordered water molecules in the back of I helix
(labeled a, b, c, and d). The putative proton delivery pathway from
conserved Thr246 to bulk solvent is shown, involving water
molecules found in the ‘solvent channel’ between the F, E and I
helices. The solvent accessible surface is shown (calculated after
removing all waters, testosterone and the heme from the
structure). For clarity, only a selection of the hydrogen bonds of
the waters with protein atoms are shown. Residue Glu245 does
not participate in the hydrogen bond network.
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lack sufficient regio- and stereoselectivity. Low solubil-
ity and generally low expression levels of mammalian
P450s further hinder their biotechnological use [42]. In
contrast, the successful development of a CYP109E1-
catalyzed whole-cell system for the production of
16b-hydroxylated testosterone, as reported here,
Fig. 8. Multiple corticosterone binding in CYP109E1. (A) Representation of intermolecular packing interactions in the crystal lattice of
CYP109E1-COR4. The mobility of the F and G helices, FG and BC-loop is restricted, thus locking the CYP109E1 molecules in an open state.
(B) Close up on multiple corticosterone binding orientations in CYP109E1 and recognition of COR-1. Hydrogen-bonding interactions of COR-
1 are shown as black dashed lines. Black mesh is the composite omit 2Fo  Fc electron density map, calculated at 2.2 A resolution and
contoured at 1r.
Fig. 9. Main productive testosterone binding mode in CYP109E1. (A) Representation of the most frequently visited testosterone
conformation in the hydrophobic active site of CYP109E1 during molecular dynamics simulations. The C16 atom of testosterone is at an
appropriate distance and angle from the oxoferryl oxygen atom to allow abstraction of its 16b-hydrogen, in accordance with the formation of
the main observed turnover product, 16b-hydroxytestosterone. Testosterone is drawn in light blue-colored sticks and the hypothetical heme
oxoferryl moiety (Fe(IV) = O or compound I) is in orange. The locations of the two C16-hydrogens targeted in predictions by MD simulations
are shown by arrows. Distances are given in angstroms next to the black dashed lines. (B) Surface representation of the same binding
mode as depicted in panel A, coloring apolar–polar, orange-blue.
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demonstrates the potential of this bacterial enzyme for
biotechnological applications.
To further improve CYP109E1 for biotechnological
purposes and to better understand its structure-
function relationships, crystal structures of CYP109E1
with and without steroids were obtained, revealing
interesting features related to steroid binding and pro-
tein conformational dynamics. The structures confirm
the general view that P450s possess a highly dynamic
active site, which exists in a primarily open state in the
absence of bound substrate, but changes toward a
more closed state when the substrate is bound. Unex-
pectedly, and for the first time, crystal structures have
revealed a P450 distal pocket with either four ligand
molecules or only a single ligand molecule bound in a
distinct way. Arguably, the presence of four bound
corticosterone molecules in the open active site pocket
of CYP109E1 is a crystallographic artifact, as it is
influenced by the high concentration of the steroid in
the crystal-binding experiment. Furthermore, crystal-
packing interactions in the CYP109E1-COR4 structure
effectively lock CYP109E1 in an open conformation,
resisting the conversion into the closed structure
expected upon substrate binding. On the other hand,
the crystallographically observed binding of multiple
corticosterone steroids to the open form of CYP109E1
may represent a snapshot of the initial substrate recog-
nition and binding events. Multiple substrate binding
occurs in other P450s, and has been implicated in the
mechanisms of homo- and heterotopic cooperativity
observed in mammalian P450s enzymes [43,44]. There
are no indications, however, for cooperative steroid
binding by CYP109E1, as evident from the hyperbolic
binding curves derived from the P450 spectral shift
titration assays (no sigmoidal fit).
The single steroid-bound structures of CYP109E1 in
the closed conformation, complemented with the MD
simulations and site-directed mutagenesis results, pro-
vide clear insights on how this enzyme accomplishes
selective 16b-hydroxylation of testosterone. The nar-
row shape of the active site pocket in the closed form
of the enzyme, and the almost exclusively hydrophobic
surface of the active site walls near the heme, restrict
the binding modes of the steroids to an orientation in
which their longitudinal axis is roughly perpendicular
to the heme plane. Two main binding modes are possi-
ble for 3-oxo-D4-steroids like testosterone and corticos-
terone, with either the C3-keto oxygen down (toward
heme) and C17-substituent up (away from heme) or
with the C17-substituent down and C3-keto oxygen
up. The first binding mode may have a possible inhibi-
tory effect, by preventing oxygen binding to the heme-
iron. Although it should be noted that coordination of
the keto C3-group is less likely to occur with reduced
iron in the ferrous state. The second binding mode
may lead to 16b-hydroxylation for steroids carrying a
small C17 substituent, like testosterone, as supported
by the MD simulations which show a substantial num-
ber of pro-16b productive conformations. Bulky polar
C17 substituents (as in corticosterone) most probably
cause a steric hindrance, blocking an optimal approach
of the C16 carbon to the heme-iron, and result in
steroids being bound in unproductive conformations
(as supported by our MD simulations with corticos-
terone). For testosterone, a third, minor productive
binding mode positions the a-face of the C17 carbon
close to the heme-iron, (in MD simulations a few pro-
17a near-attack conformations were observed), so that
a second hydroxylation at this position can occur fol-
lowed by removal of a water molecule, explaining the
production of androstenedione as a side product. A
similar oxidation reaction has very recently been
observed with CYP106A1 where an 11-oxidase activity
toward 11-hydroxy steroids was demonstrated [19,45].
The molecular basis for the stereoselectivity of
CYP109E1 toward 16b-hydroxylation of testosterone
is further clarified by a structural comparison with
CYP154C5, which converts testosterone to 16a-
hydroxytestosterone. The shape and volume of the
active site pockets in the testosterone-bound crystal
structures of these two enzymes are significantly differ-
ent, which is primarily due to the highly variable BC
loop. This loop is much longer in CYP154C5 and
functions as a lid that almost completely locks the
active site pocket. A closure to this extent is not
observed in the testosterone-bound CYP109E1 struc-
ture. Although near to the heme, the active site pocket
in testosterone-bound CYP109E1 is more restricted
Table 3. Effect of introduced mutations on production of 16-b-
hydroxytestosterone (16b-OH-TES) by CYP109E1 enzyme variants.
The in vitro reactions were carried out in 50 mM potassium
phosphate buffer with 2% glycerol, pH 7.4, at 30 °C for 30 min.
Bovine Adx4–108 and AdR were used as redox partners and 200 lM
of substrate dissolved in DMSO was added. Shown are the mean
values and standard deviations (SD) of three independent
measurements.
CYP109E1 variant
Catalytic activity for the
formation of 16b-OH-TES,
nmol(nmol P450)1min1
WT 4.35  0.02
K187A 1.43  0.06
V169A 0.07  0.02
I241A 0.01  0.01
E245A 4.69  0.04
T246A 0.12  0.04
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compared to CYP154C5, near its entrance, it is more
open and accessible to solvent. The different shapes of
the active site pockets are coupled to different orienta-
tions of the bound steroids relative to the heme plane:
roughly perpendicular in the CYP109E1-TES struc-
ture, while more-or-less parallel in the CYP154C5-TES
complex. While the perpendicular binding mode of
testosterone is optimal for C-H abstraction from the
b-face of the C16 carbon, the parallel binding orienta-
tion in CYP154C5-TES positions the a-face of the
testosterone C16 carbon close to the heme-iron,
explaining the difference in stereoselectivity of these
enzymes [14]. The parallel binding orientation of
testosterone in CYP154C5 is stabilized by interactions
of the apolar steroid ring system with hydrophobic
residues from two opposite regions (BC loop and I
helix) in the active site pocket. The polar C17 sub-
stituent forms a hydrogen bond with Gln398 (from
SRS6), while the C3 substituent is bound near to
Gln239 in a solvent-accessible pocket. In CYP109E1,
the equivalent residues to Gln239 and Gln398 of
CYP154C5 are Ile237 and Val392, respectively
(Fig. 6D). Lack of polar residues in the active site
pocket near the heme thus prevents a similar binding
orientation of testosterone in CYP109E1 as in
CYP154C5. In addition, the side chains of Leu80 (BC
loop) and Ile241 (I helix) in CYP109E1 pose a steric
hindrance to the incoming steroid molecule, favoring a
perpendicular over a parallel binding orientation.
Thus, the difference in stereoselectivity between
CYP109E1 and CYP154C5 toward C16-hydroxylation
of testosterone is a result of the differences in the
shape and the apolar/polar surface distribution of their
active site pocket, leading to a different binding orien-
tation of the steroid relative to the heme.
In conclusion, we have identified CYP109E1 as a
novel steroid-hydroxylating cytochrome P450 enzyme
from Bacillus megaterium DSM319, with the ability to
selectively convert testosterone to 16b-hydroxytestos-
terone. Our combined structural, biochemical, and
molecular modeling studies provided several insights
into the molecular basis of steroid binding by
CYP109E1 and of its regio- and stereoselectivity
toward testosterone. First, binding of single steroid
molecules like testosterone and corticosterone stabilizes
a change in the active site pocket toward a more
closed and narrow conformation. The steroid-induced
structural changes include the local widening of the
central I helix, which is coupled with the formation of
a water channel believed to function as a water access
channel and/or proton delivery network during cataly-
sis. Secondly, the steroids may bind in two opposite
orientations, with either their C3-keto oxygen or their
C16 carbon and C17 substituent directed toward the
heme. The first orientation leads to nonproductive
binding. The second orientation results in productive
binding for testosterone, and nicely explains the high
selectivity toward 16b-hydroxylation. The larger C17
substituent of corticosterone, and the presence of its
C21-hydroxyl group, prohibit productive binding of
this steroid. Our results will facilitate future protein




The steroid compounds used in this study were obtained
from Sigma-Aldrich (Steinheim, Germany). All other chem-
icals were of highest grade available.
Bioinformatics analysis
Identification of close homologs and comparison of protein
sequences were performed using the Basic Local Alignment
Search Tool (BLAST, NCBI). Multiple sequence alignment
was done with Clustal Omega [46] and visualized with
ESPript3 [47]. Evolutionary analysis was carried out using
Molecular Evolutionary Genetics Analysis (MEGA) version
6.0 software [48]. The phylogenetic tree was constructed
using the Neighbor-joining method [49] and the evolution-
ary distances were computed using the Poisson correction
method [50].
Cloning of wild-type enzyme
The gene encoding CYP109E1 (GenBank GeneID 9119265)
was amplified by the PCR using genomic DNA of B. mega-
terium MS941, a mutant form of B. megaterium, derived
from the DSM319 strain [51]. The PCR primers were
designed (MWG-Biotech AG, Ebersberg, Germany) to
introduce an NdeI restriction site at the 50 end of the frag-
ment and a KpnI restriction site with a 6-histidine tag at
the 30 end. Following the amplification of the cyp109e1
gene, the PCR product was cloned into the pCR4Bl-TOPO
vector (Invitrogen, San Diego, CA, USA) and the vector
was further digested with the restriction enzymes cutting at
the above-mentioned sites and ligated into the expression
vector pET17b (Merck Bioscience, Bad Soden, Germany),
creating the pET17b_109E1 vector. The cyp109e1 gene was
further amplified by PCR from the previously constructed
pET17b expression vector using PCR primers designed to
include a SpeI restriction site at the 50 end and a KpnI
restriction site at the 30 end of the fragment. The resulting
PCR product was subcloned in the pCR4-TOPO vector
and digested with the corresponding restriction enzymes.
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The fragment was then ligated to the previously linearized
pSMF2.1 vector [52], yielding the pSMF2.1E construct.
Sequences of the designed primers are given in supplemen-
tary Table S1. Sequences of all created vectors were verified
by DNA sequencing, carried out by Eurofins-MWG
(Ebersberg, Germany).
Site-directed mutagenesis
The mutants of CYP109E1 were generated by the Quik-
Change site-directed mutagenesis method using the plasmid
pET17b_109E1 as template and Phusion polymerase for
DNA replication (Thermo Fisher Scientific GmbH, Dreir-
eich, Germany). The reactions were performed in 50 lL,
using a gradient cycler (PTC-200 DNA Engine cycler).
Twenty cycles were carried out as follows: initial denatura-
tion at 95 °C for 30 sec, denaturation at 95 °C for 30 sec,
annealing at 58 °C for 30 sec, and extension at 72 °C for
4 min. The oligonucleotide primers for mutagenesis are
shown in Table S1. Correct generation of the desired muta-
tions was confirmed by DNA sequencing.
Expression and purification
A 30-mL preculture of E. coli C43 (DE3) cells carrying the
pET17b_109E1 vector was grown overnight in LB medium
containing 100 lgmL1 ampicillin at 37 °C (150 rpm).
This culture was used to inoculate a 1.2-L production cul-
ture, divided over four 2-L baffled flasks, in Terrific Broth
(TB) medium containing 100 lgmL1 ampicillin. Cultiva-
tion was continued at 37 °C (150 rpm) until the OD600
reached 0.5, after which 1 mM IPTG and 0.5 mM d-amino-
levulinic acid were added to start protein expression and
support heme synthesis, respectively. After 24 h of incuba-
tion at 30 °C, 100 rpm, the cells were harvested by centrifu-
gation (4500 g for 35 min) and the cell pellet was stored at
20 °C until further use. All purification steps were per-
formed at 4 °C. For crystallization and spectral characteri-
zation of wild-type CYP109E1, a three-step purification
procedure was applied, starting with resuspension of the
cell pellet in 100 mL cold lysis buffer containing 50 mM
Tris/HCl, pH 8.0, 1 mM EDTA, 20 mM NaCl, and 0.1 mM
dithioerythritol, followed by the addition of 50 lgmL1
PMSF. The mixture was sonicated for 15 min (15 sec on,
15 sec off) on ice and, subsequently, the same amount of
PMSF was added. Cell-free extract was obtained by ultra-
centrifugation at 40 000 g for 35 min at 4 °C. The super-
natant containing CYP109E1 was loaded onto a 50-mL
SOURCE 30Q anion-exchange column (GE Healthcare,
Solingen, Germany) equilibrated with three column vol-
umes of 20 mM Tris/HCl, pH 7.4, 0.1 mM dithioerythritol.
The column was washed with the same buffer before elu-
tion of CYP109E1 with a linear gradient of 0–500 mM
NaCl. Fractions with the highest A418/A280 ratio were
combined and concentrated by ultrafiltration using a 30-
kDa cutoff membrane (Amicon Ultra/Millipore). The pro-
tein concentrate was then manually loaded onto a Superdex
75 (200 mL) gel filtration column (GE Healthcare) and
CYP109E1 was eluted with 50 mM potassium phosphate
buffer, pH 7.4, 0.1 mM dithioerythritol. The fractions with
the highest A418/A280 ratio were pooled, diluted 1:5 with
5 mM potassium phosphate buffer, pH 7.4 and 0.05 mM
dithioerythritol, before loading them onto a hydroxyapatite
column (50 mL, Bio-Rad, Hercules, CA, USA). The col-
umn was washed with 10 mM potassium phosphate buffer,
pH 7.4, 0.1 mM dithioerythritol, and CYP109E1 was eluted
with a buffer concentration gradient ranging from 10 to
100 mM. Fractions containing purified CYP109E1 with an
A418/A280 ratio larger than 1.6 were collected, concentrated
by ultrafiltration using a 30-kDa cutoff membrane, and
stored at 80 °C after flash-freezing in liquid nitrogen. For
in vitro conversion experiments, the wild-type protein and
its mutants were purified with an alternative one-step
purification procedure. The cell pellets were resuspended in
50 mM potassium phosphate buffer, pH 7.4, containing
300 mM NaCl and 20% glycerol. Then, PMSF was added to
a final concentration of 1 mM and the suspension was soni-
cated for 15 min (15 sec on, 15 sec off) on ice. Cell-free
extract was obtained by ultracentrifugation at 30 000 rpm
for 30 min, at 4 °C. The supernatant was applied to immo-
bilized metal ion affinity chromatography column (TALON,
Takara Bio Europe, Saint-Germain-en-Laye, France) equili-
brated with 50 mM potassium phosphate buffer, pH 7.4,
containing 300 mM NaCl and 20% glycerol. The column
was washed with 5 column volumes of the same buffer con-
taining 20 mM imidazole, and the tagged protein was eluted
with a buffer containing 150 mM imidazole.
Enzyme analysis
The UV/Vis spectra of the purified protein were recorded
using a double-beam spectrophotometer (UV-2101PC, Shi-
madzu, Japan) from 200 to 700 nm. CYP109E1 concentra-
tions were determined by CO-difference spectroscopy of the
reduced protein, following the method of Omura and Sato
[53] and using an extinction coefficient of 91 mM1cm1.
Protein purity was analyzed by SDS/PAGE.
Difference spectroscopy and determination of
dissociation constants (KD)
Substrate-induced spin-shift states were studied via a dou-
ble-beam spectrophotometer (UV-2101PC, Shimadzu,
Japan), using tandem quartz cuvettes, according to the
method of Schenkman and Jansson [54]. One of the cuvette
chambers contained the purified CYP109E1 protein solu-
tion (10 lM) in 50 mM potassium phosphate buffer, pH 7.4,
while the other chamber was filled with the corresponding
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buffer only. The steroids were dissolved in DMSO (2.5–
20 mM stock solutions) and the enzyme solution was
titrated with increasing amounts of testosterone or corticos-
terone, in the range of 0–200 lM or until saturation was
reached, while the spectrum was recorded between 350 and
500 nm. All titrations were carried out in triplicates. The
data were analyzed by plotting the peak-to-trough differ-
ences (DA: AmaxAmin) against the steroid concentrations.
The subsequent hyperbolic fitting was performed using
ORIGIN software (OriginLab Corporation, Northampton,
MA, USA), and the equilibrium dissociation constants (KD)
were determined with a regression coefficient of R2 = 0.99.
In vitro substrate turnover
The in vitro turnover of tested steroids was performed in a
final volume of 250 lL, using 50 mM potassium phosphate
buffer with 2% glycerol, pH 7.4, at 30 °C for 30 min. The
reconstituted system contained CYP109E1 (1 lM), bovine
Adx4–108 (20 lM), AdR (2 lM), a NADPH-regenerating sys-
tem (1 mM MgCl2, 5 mM glucose-6-phosphate, 1 U glucose-
6-phosphate dehydrogenase) and 200 lM of the correspond-
ing steroid dissolved in DMSO. The reactions were initiated
by the addition of NADPH to a final concentration of
1 mM, then stopped and extracted twice with the addition of
250 lL of ethyl acetate. The samples were centrifuged
(10 000 rpm, 10 min), the organic phases were combined
and evaporated until complete dryness and, after resuspen-
sion, analyzed by HPLC. Since, the absorption properties of
the products did not differ from the respective substrates,
the product formation was calculated from the relative peak
area (area %) of the HPLC chromatograms, dividing each
respective product peak area by the sum of all peak areas.
Whole-cell conversion with Bacillus megaterium
MS941
The in vivo conversions were done with the B. megaterium
strain MS941 [51]. The MS941 cells were transformed with
the pSMF2.1E vector, using the polyethylene glycol-mediated
protoplast transformation method [55]. For cultivation, a
complex medium was used (24 gL1 yeast extract, 12 gL1
soytone, 2.31 gL1 KH2PO4, and 1.25 gL1 KHPO4) sup-
plemented with 10 lgmL1 tetracycline at 30 °C, 180 rpm.
First, a 50-mL overnight culture was prepared, inoculated
from a 80 °C glycerol stock of the transformed MS941 cells.
This culture was then used to inoculate the main culture in a
300-mL baffled shake flask filled with 50 mL complex med-
ium. The main culture was incubated, until the OD578 reached
0.4, when the protein expression was induced by the addition
of xylose at a final concentration of 5 mgmL1. After 24 h,
the cultures were harvested by centrifugation (15 min,
10 000 g, 4 °C) and the pellets resuspended in 50 mL of
50 mM potassium phosphate buffer, pH 7.4. The substrates,
dissolved in DMSO, were added at a final concentration of
200 lM. The 500 lL samples were taken from the cultures at
fixed time points, followed by extraction and HPLC analysis.
To obtain sufficient product quantities for structural analysis
by NMR spectroscopy (mg range), the volume of the main
culture was increased to 750 mL (3 9 250 mL) in 2-L baffled
flasks. After a 24-h expression period, the cultures were har-
vested by centrifugation, resuspended in 375 mL of 50 mM
potassium phosphate buffer, pH 7.4, and the corresponding
substrates were added at a final concentration of 300 lM. Fol-
lowing the conversion, the cultures were extracted twice with
ethyl acetate, the organic phases were combined and evapo-
rated (Rotavapor R-114; B €UCHI Labortechnik AG, Flawil,
Switzerland). The purification and isolation of products was
carried out by preparative HPLC.
HPLC analysis and product isolation
The HPLC analyses were carried out with a Jasco system
(Pu-980 HPLC pump, AS-950 sampler, UV-975 UV/visible
detector, LG-980-02 gradient unit; Jasco, Gross-Umstadt,
Germany), using a reversed-phase ec MN Nucleodur C18
(3 lM, 4.0 9 125 mm) column (Macherey-Nagel, Bethle-
hem, PA, USA) kept at an oven temperature of 40 °C. The
steroids were eluted using a gradient method, starting with
a mobile phase consisting of acetonitrile:H2O in a ratio of
1:9, increasing it to 1:1. The flow rate was 1 mLmin1 and
the UV detection of the substrate and product was accom-
plished at 240 or 254 nm. For product isolation, the dis-
solved extracts were filtered (Acrodisc PTFE syringe filter,
0.45 lm, PALL) and injected to a reversed-phase ec MN
Nucleodur C18 (5 lM, 8.0 9 250 mm) column (Macherey-
Nagel, Bethlehem, PA, USA). The HPLC run was carried
out analogously to the analytical HPLC conditions with an
increased flow rate of 2.5 mLmin1. Fractions were col-
lected with an Advantec CHF122 SB fraction collector,
combined, and evaporated on a rotary evaporator (Rotava-
por R-114 from B €UCHI Labortechnik AG).
NMR spectroscopy
The NMR spectra were recorded in deuterated chloroform
(CDCl3) with a Bruker DRX 500 or a Bruker Avance 500
NMR spectrometer at 300 K. The chemical shifts were rel-
ative to CDCl3 at d 24.7 (
1H NMR) and 77.00 (13C NMR),
using the standard d notation in parts per million. The 1D
NMR (1H and 13C NMR, DEPT135) and the 2D NMR
spectra (gs-HH-COSY, gs-NOESY, gs-HSQCED, and gs-
HMBC) were recorded using the BRUKER pulse program
library. All assignments were based on extensive NMR
spectral evidence.
Crystallization
After thawing, aliquots of purified CYP109E1 were buffer
exchanged to 20 mM Tris/HCl, pH 8.0, 0.1 mM
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dithioerythritol using a PD-10 desalting column (GE
Healthcare) and concentrated to 40 mgmL1. Screening
for crystallization growth conditions was done at 293 K by
the sitting-drop vapor-diffusion method, using 96-well crys-
tallization plates, a Mosquito crystallization robot, (TTP
LabTech, Melbourn, UK) and a few commercially avail-
able screens. Lead crystallization conditions were optimized
manually in 24-well plates at 293 K. Initial crystals grew
with a reservoir solution containing 25% poly(ethylene gly-
col) 3350, 0.1 M Bis-tris, pH 6.5, and 4% tacsimate reagent
(pH 6.0) (Hampton Research, Aliso Viejo, CA, USA).
Diffraction quality crystals were obtained by applying a
streak-seeding protocol. First, protein drops were prepared
by mixing 2 lL of concentrated CYP109E1 (40 mgmL1)
with an equal volume of reservoir solution, containing 20%
poly(ethylene glycol) 3350, 0.1 M Bis-tris, pH 6.5, and 4%
tacsimate reagent pH 6.0. Droplets were equilibrated
against 500 lL of the reservoir solution for 1 h, and then
streak-seeded. Red-colored, cubic-shaped crystals of
CYP109E1 (space group P3221) grew overnight and
reached a final average size of approximately
0.15 9 0.15 9 0.15 mm3 in about 7 days. Corticosterone-
bound CYP109E1 crystals were initially obtained by crystal
soaking experiments. For this, corticosterone was added as
a solid powder directly into crystallization drops containing
native CYP109E1 crystals, followed by equilibration
against the original crystallization solution for 3–4 weeks.
Alternatively, cocrystallization screens were employed with
corticosterone and testosterone (in a 1:5 molar ratio of pro-
tein:steroid, using stocks solutions of the steroids in
DMSO), resulting in large cuboid-shaped crystals (space
group P21) grown from 9% poly(ethylene glycol) 3350 and
8% tacsimate pH 5.0 (Hampton Research). Prior to data
collection, crystals were briefly soaked in a cryoprotectant
solution containing mother liquor, supplemented with 20%
(v/v) glycerol. Cryoprotection of crystals obtained by
cocrystallization was accomplished by raising the poly(ethy-
lene glycol) 3350 concentration to 35%. Subsequently, all
crystals were flash-cooled at 100 K in the cold nitrogen gas
stream of the camera’s cryostat.
Data collection and structure determination
X-ray diffraction data were collected at the ID29, ID23-1,
and ID23-2 beam lines of the European Synchrotron Radi-
ation Facility (ESRF), Grenoble, all equipped with Pilatus
detectors. Additional data were recorded using an in-house
rotating anode X-ray source (Bruker MicroSTAR) and an
image plate detector (mar345TM). Single crystals of
CYP109E1 were used to obtain diffraction datasets in the
2.55–2.1 A resolution range. Reflections were indexed and
integrated using iMosflm [56] or XDS [57], while scaling
and merging of the data was done with AIMLESS from
the CCP4 software suite [58]. The structure of native
CYP109E1 was solved by molecular replacement with
Phaser from the PHENIX suite [59], using the structure of
HmtT from Streptomyces himastatinicus (PDB ID 4ggv,
39% sequence identity) as a search model. Two protein
molecules were located in the asymmetric unit, consistent
with Matthew coefficient calculations indicating a solvent
content of 61%. Automatic model rebuilding using routines
in PHENIX yielded approximately 80% of the polypeptide
model. The model was completed by iterative cycles of
model building with Coot [60] and structure refinement
with Phenix.refine [61]. The structure of substrate-free
CYP109E1 then served as a starting point to solve the
CYP109E1 steroid-bound structures. At the final stages of
refinement, water molecules were added to the structures
based on peaks in the electron density maps and using
strict interaction criteria. The quality of the refined protein
models was validated using MolProbity [62].
Structure analysis
Pairwise comparison of the obtained structures with other
P450 structures and RMSD calculations were done with
the PDBeFold engine [63] Protein–ligand interactions were
analyzed by LigPlot+ [64]. Substrate recognition sites (SRS)
in CYP109E1 were identified based on alignment with
P450cam and the description provided by Gotoh [29]. The
respective residue ranges in CYP109E1 are: SRS1 67–89,
SRS2 165–171, SRS3 187–194, SRS4 230–249, SRS5 286–
295, and SRS6 388–395.
Molecular dynamics simulations
Molecular dynamics simulations were performed using the
CYP109E1-TES crystal structure as a starting model, fol-
lowing the same procedure as previously described [33].
First, testosterone and all water molecules were removed
from the crystal structure, and the heme and its cysteine
ligand were replaced by a model of heme compound I
covalently bound to cysteine. The tested ligand (testos-
terone or corticosterone) was then manually placed back in
the binding pocket using PyMOL (Schr€odinger, Cambridge,
MA, USA). Testosterone was placed in 10 different starting
orientations where the distance between the C16b hydrogen
and the ferryl oxygen atom of heme compound I was less
than 4 A. Corticosterone was placed in starting orientations
similar to the COR-1 steroid orientation in the CYP109E1-
COR4 crystal structure. To ensure extensive conforma-
tional sampling, ten 100-ns MD simulations with different
initial orientations of the steroid were performed for each
CYP109E1-steroid system, and the AMBER03 force field
[65] in GROMACS version 5.0.4 was used [66]. Force fields for
testosterone and corticosterone were generated by use of
the structures derived from the PubChem database [67]
and subsequent energy minimization in YASARA
(www.YASARA.org). The RESP partial charges of the
molecules were calculated using the R.E.D webserver with
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the RESP-A1B charge model [68]. The force field was built
with the ANTECHAMBER module of AMBER 10 [69]
and converted into the GROMACS topology format. The
force field of the cysteine-heme compound I complex was
used as previously described [70]. An octahedral water box
of SPC/E water with periodic boundaries at least 1.2 nm
from the protein was used. Simulations were run at 300 K
and 1 bar. Pressure coupling was performed with a Par-
rinello–Rahman barostat [71]. The Nose–Hoover coupling
scheme was used to maintain the temperature, with cou-
pling constant of 0.5 ps [72]. Initial velocities were ran-
domly assigned. The LINCS algorithm was applied to
constrain all bonds containing hydrogen atoms [73]. Seven-
teen sodium counter ions were added to maintain the neu-
tral charge of the systems. Long-range electrostatic
interactions were treated by using the particle-mesh Ewald
method [74]. Energy minimization was performed using the
steepest descent method with positional restraints on pro-
tein heavy atoms and a maximum allowed force of
1000 kJmol1nm1. A 2-fs time step was used and coordi-
nates were saved every 1000 steps (2 ps). To determine
near-attack conformations the distance between the 16a or
16b hydrogen and the ferryl oxygen of compound I ferryl
oxygen was measured. In case of simulations with testos-
terone, additionally the distance between the 17a hydrogen
and the ferryl oxygen was measured. Angles between the
C16 or C17 carbon, their hydrogens and the ferryl oxygen
were also measured. Based on the previously described cut-
offs [33–35], ligand conformations were considered near to
attack, if at least one of the measured distances was < 3.5
A and the angle was 180  45°. All other conformations
were considered nonproductive. The number of frames in
MD trajectories suggesting pro-16a, pro-16b, pro-17a, and
nonproductive conformations were counted and expressed
as percentages.
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